Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;43(5):975-981.
doi: 10.1007/s00296-023-05309-2. Epub 2023 Mar 15.

Takayasu arteritis associated with autoimmune/inflammatory syndrome induced by adjuvants: a case-based review

Affiliations
Review

Takayasu arteritis associated with autoimmune/inflammatory syndrome induced by adjuvants: a case-based review

Desislava Simeonova et al. Rheumatol Int. 2023 May.

Abstract

Takayasu's arteritis (TA) is a chronic granulomatous vasculitis that predominantly affects the aorta and its major branches. Despite advancements in the understanding of the pathogenic pathways of vascular inflammation, the etiology and predisposing factors of TA remain to be fully understood. In susceptible individuals, exposure to adjuvants may trigger, unlock or unmask an autoimmune disorder, presenting as non-specific constitutional symptoms or a fully developed autoimmune syndrome such as vasculitis. Here, we hypothesize that TA could be triggered by siliconosis, a subtype of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). ASIA, also known as Shoenfeld syndrome, encompasses a wide range of autoimmune and immune-mediated diseases resulting from dysregulation of the immune response after exposure to agents with adjuvant activity. This case report describes the development of large artery vasculitis, TA, in an individual one year following the placement of silicone breast implants. The patient initially presented with non-specific symptoms, and multiple imaging methods were employed, including ultrasound diagnostics, CT angiography, and 18-fluorodeoxyglucose positron emission tomography/CT. These techniques revealed vasculitic alterations in the carotid arteries and thoracic aorta. Initial treatment with glucocorticosteroids proved ineffective, prompting the addition of steroid-sparing immunosuppressive agents. Due to the distinct clinical symptoms, disease progression, implant-associated fibrosis, and resistance to therapy, the potential involvement of implants in the development of large-vessel vasculitis was considered, and a potential association with ASIA was postulated. Although there is limited evidence to support a direct link between adjuvants and the pathogenesis of TA, similarities in cellular immunity between the two conditions exist. The diagnosis of this complex and potentially debilitating condition requires a comprehensive clinical examination, laboratory evaluation, and instrumental assessment. This will aid in identifying potential contributing factors and ensuring successful treatment.

Keywords: Autoimmune/inflammatory syndrome induced by adjuvants; Autoimmunity; Breast implants; Case report; Immunologic adjuvants; Large vessel vasculitis; Silicone gels; Takayasu arteritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Images of 18-FDG PET/CT and three-dimensional computed tomography showing: A an 18-FDG PET/CT showing an increased metabolic activity in the wall of the ascending aorta and aortic arch. Increased glucose metabolism is also detected around the implants and paraspinal muscles suggesting pericapsular inflammation and paraspinal myositis. B An 18-FDG PET/CT showing heightened glucose metabolism in lower legs and upper extremity proximal muscles. C A three-dimensional computed tomography (3D CT) reconstruction image of the descending aorta stenosis
Fig. 2
Fig. 2
Differences in the angiographic findings of the thoracic aorta between 2020 (A) and 2022 (B) show a significant regression in the thickness of the aortic wall and an increase in the vascular lumen
Fig. 3
Fig. 3
Flow diagram showing the number of identified, screened, eligible and included studies

References

    1. Zaldivar Villon MLF, de la Rocha JAL, Espinoza LR. Takayasu arteritis: recent developments. Curr Rheumatol Rep. 2019;21:45. doi: 10.1007/s11926-019-0848-3. - DOI - PubMed
    1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919–929. doi: 10.7326/0003-4819-120-11-199406010-00004. - DOI - PubMed
    1. Wong SPY, Mok CC, Lau CS, et al. Clinical presentation, treatment and outcome of Takayasu’s arteritis in southern Chinese: a multicenter retrospective study. Rheumatol Int. 2018;38:2263–2270. doi: 10.1007/s00296-018-4150-x. - DOI - PubMed
    1. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheumatol. 2007;56:1000–1009. doi: 10.1002/art.22404. - DOI - PubMed
    1. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR classification criteria for takayasu arteritis. Arthritis Rheumatol. 2022;74:1872–1880. doi: 10.1002/art.42324. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources